| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | -0.0078 | 0.8 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.0071 | 0.8 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0077 | 0.8 |
| mRNA | C6-ceramide | CTRPv2 | pan-cancer | AAC | 0.0082 | 0.8 |
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.8 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | -0.0079 | 0.8 |
| mRNA | Z-LLNle-CHO | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.0071 | 0.8 |
| mRNA | OSI-930 | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.8 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | 0.008 | 0.8 |